These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31851760)

  • 1. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.
    Neumeyer J; Lin RZ; Wang K; Hong X; Hua T; Croteau SE; Neufeld EJ; Melero-Martin JM
    Blood Adv; 2019 Dec; 3(24):4166-4176. PubMed ID: 31851760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of the human F8 at the multicopy rDNA locus in Hemophilia A patient-derived iPSCs using TALENickases.
    Pang J; Wu Y; Li Z; Hu Z; Wang X; Hu X; Wang X; Liu X; Zhou M; Liu B; Wang Y; Feng M; Liang D
    Biochem Biophys Res Commun; 2016 Mar; 472(1):144-9. PubMed ID: 26921444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A.
    Rose M; Gao K; Cortez-Toledo E; Agu E; Hyllen AA; Conroy K; Pan G; Nolta JA; Wang A; Zhou P
    Stem Cells Transl Med; 2020 Jun; 9(6):686-696. PubMed ID: 32162786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells.
    Jia B; Chen S; Zhao Z; Liu P; Cai J; Qin D; Du J; Wu C; Chen Q; Cai X; Zhang H; Yu Y; Pei D; Zhong M; Pan G
    Life Sci; 2014 Jul; 108(1):22-9. PubMed ID: 24834837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A.
    Olgasi C; Talmon M; Merlin S; Cucci A; Richaud-Patin Y; Ranaldo G; Colangelo D; Di Scipio F; Berta GN; Borsotti C; Valeri F; Faraldi F; Prat M; Messina M; Schinco P; Lombardo A; Raya A; Follenzi A
    Stem Cell Reports; 2018 Dec; 11(6):1391-1406. PubMed ID: 30416049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of
    Zhao J; Zhou M; Wang Z; Wu L; Hu Z; Liang D
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
    J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
    Liu L; Mah C; Fletcher BS
    Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
    Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
    PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A.
    Xiao R; Chen Y; Hu Z; Tang Q; Wang P; Zhou M; Wu L; Liang D
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency.
    Roualdes O; Nougier C; Fretigny M; Talagrand E; Durand B; Negrier C; Vinciguerra C
    Haemophilia; 2015 May; 21(3):e202-e209. PubMed ID: 25708597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
    Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
    Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs.
    Wu Y; Hu Z; Li Z; Pang J; Feng M; Hu X; Wang X; Lin-Peng S; Liu B; Chen F; Wu L; Liang D
    Sci Rep; 2016 Jan; 6():18865. PubMed ID: 26743572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.
    Chen H; Shi M; Gilam A; Zheng Q; Zhang Y; Afrikanova I; Li J; Gluzman Z; Jiang R; Kong LJ; Chen-Tsai RY
    Sci Rep; 2019 Nov; 9(1):16838. PubMed ID: 31727959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A.
    Gong J; Chung TH; Zheng J; Zheng H; Chang LJ
    J Biol Chem; 2021 Dec; 297(6):101397. PubMed ID: 34774524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Therapy for Hemophilia A: Where We Stand.
    Zhou M; Hu Z; Zhang C; Wu L; Li Z; Liang D
    Curr Gene Ther; 2020; 20(2):142-151. PubMed ID: 32767930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.